(CKD) in adults, and risk of adverse outcomes by category In August 2021, the National Institute for Health and Care Excellence (NICE) published NG203,2 an updated and combined version of three guidelines: "chronic kidney disease in adults: assessment and management," "chronic kidney disease ...
1.6Statinsforprimarypreventionofcardiovasculardisease17 1.7Lipid-loweringtreatmentforsecondarypreventionofcardiovasculardisease19 1.8Statinsforprimaryandsecondarypreventionofcardiovasculardiseaseinpeoplewith chronickidneydisease22 1.9Optimisingtreatmentforpeopleonstatins23 ...
1.5Treatingheartfailure with reduced ejection fraction in people with chronic kidney disease... 16 1.6 Managing all types of heart failure... 17 1.7 Monitoring treatment for all types of heart failure ...
managementforpeoplewithchronickidneydiseasestages4and5.Itaimstoimprovequalityoflife bymakingrecommendationsonnning,startingandswitchingtreatments,andcoordinating care. NICEhasalsoproducedaguidelineonchronickidneydiseaseinadults. Whoisitfor? Healthcareprofessionals ...
Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical prac... S Carville,D Wonderling,P ...
Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance [J]. BMJ, 2014, 349:4507.England: Chronic Kidney Disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. NICE. 2014; Available: http:...
Bone disease and ectopic calcification are the two main consequences of hyperphosphataemia of chronic kidney disease (CKD). Observational studies have demonstrated that hyperphosphataemia in CKD is associated with increased mortality. Furthermore, the use of phosphate binders in dialysis patients is asso...
Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca's SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft recommendations. AZ said that the decision is a "milestone" in t
NICE also provides guidance on drugs to avoid. Plant stanols, sterols, omega 3 fatty acids, fibrates, resins and nicotinic acid are not recommended for the prevention of cardiovascular disease, which has the effect of streamlining lipid prescribing. ...
Introducing the updated guidance, Dr Paul Chrisp, director of NICE’s centre for guidelines, said: "Based on evidence, our committee agreed that ear drops containing an anaesthetic and an analgesic may reduce antibiotic consumption and relieve pain in children who did not need immediate antibiotics...